COMPANY PIPELINE AND TECHNOLOGY PRODUCTS CAREDX PORTAL INVESTORS CONTACT US CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions. CareDx in the News CareDx to Announce Second Quarter 2018 Financial Results on August 9, 2018 July 23, 2018 Flatiron Health CMO/CSO Joins CareDx Board of Directors June 28, 2018 CareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes June 19, 2018 Press Release Archive Information on CareDx CareDx Company Update CareDx Living Donor Employee Recovery Policy (LIDER) Learn about AlloSure AlloSure is the first and only non-invasive test that assesses organ health by directly measuring allograft injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients. Learn about AlloMap AlloMap is a non-invasive blood test that helps physicians identify the risk of acute cellular rejection in heart transplant recipients. Hear what doctors and patients say about AlloMap Upcoming Events Look for CareDx at the following 2018 events: EFI 32nd Annual Meeting 2018 Venice, Italy May 9-12, 2018 ATC 2018 Seattle, WA, United States June 2-6, 2018 ASHI 44th Annual Meeting 2018 Baltimore, MD, United States October 1-5, 2018 ©2018 CareDx, Inc. All service marks and trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved. Privacy & Compliance